| Q34978590 | A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys |
| Q34991300 | A library of functional recombinant cell-surface and secreted P. falciparum merozoite proteins |
| Q35227478 | A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein |
| Q38718229 | Accelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal 'C-tag'. |
| Q28082023 | Advances in genetics and genomics: use and limitations in achieving malaria elimination goals |
| Q92095524 | Antibodies against a short region of PfRipr inhibit Plasmodium falciparum merozoite invasion and PfRipr interaction with Rh5 and SEMA7A |
| Q91786726 | Antibody Reactivity to Merozoite Antigens in Ghanaian Adults Correlates With Growth Inhibitory Activity Against Plasmodium falciparum in Culture |
| Q42142070 | Applying Unconventional Secretion in Ustilago maydis for the Export of Functional Nanobodies |
| Q33820897 | Association of antibodies to Plasmodium falciparum reticulocyte binding protein homolog 5 with protection from clinical malaria |
| Q37548216 | Bacterially expressed full-length recombinant Plasmodium falciparum RH5 protein binds erythrocytes and elicits potent strain-transcending parasite-neutralizing antibodies |
| Q27973510 | Biochemical analysis of the Plasmodium falciparum erythrocyte-binding antigen-175 (EBA175)-glycophorin-A interaction: implications for vaccine design |
| Q35159524 | Blockade of Plasmodium falciparum erythrocyte invasion: New assessment of anti-Plasmodium falciparum reticulocyte-binding protein homolog 5 antibodies |
| Q38672088 | Blood-stage malaria vaccines: post-genome strategies for the identification of novel vaccine candidates |
| Q48014614 | CRISPR/Cas9 knockouts reveal genetic interaction between strain-transcendent erythrocyte determinants of Plasmodium falciparum invasion |
| Q36875789 | Comparison of allele frequencies of Plasmodium falciparum merozoite antigens in malaria infections sampled in different years in a Kenyan population |
| Q35167000 | Crystal structure of PfRh5, an essential P. falciparum ligand for invasion of human erythrocytes |
| Q92039518 | Design of a basigin-mimicking inhibitor targeting the malaria invasion protein RH5 |
| Q30386145 | Different Regions of Plasmodium falciparum Erythrocyte-Binding Antigen 175 Induce Antibody Responses to Infection of Varied Efficacy. |
| Q56369001 | Extent and Dynamics of Polymorphism in the Malaria Vaccine Candidate Reticulocyte-Binding Protein Homologue-5 in Kalifabougou, Mali |
| Q64093393 | Few Plasmodium falciparum merozoite ligand and erythrocyte receptor pairs show evidence of balancing selection |
| Q64967277 | Functional Comparison of Blood-Stage Plasmodium falciparum Malaria Vaccine Candidate Antigens. |
| Q36687352 | Generation of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPA |
| Q92450878 | Genetic polymorphisms in malaria vaccine candidate Plasmodium falciparum reticulocyte-binding protein homologue-5 among populations in Lagos, Nigeria |
| Q49220322 | High Level of Specific Anti-Plasmodium Falciparum Merozoite IgG1 Antibodies in Rural Asymptomatic Individuals of Dienga, South-Eastern Gabon |
| Q38376500 | Host-parasite interactions that guide red blood cell invasion by malaria parasites |
| Q92781089 | Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies |
| Q47576664 | Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions |
| Q27230019 | Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate |
| Q37233262 | Identifying novel Plasmodium falciparum erythrocyte invasion receptors using systematic extracellular protein interaction screens |
| Q42114064 | Implications from predicted B-cell and T-cell epitopes of Plasmodium falciparum merozoite proteins EBA175-RII and Rh5. |
| Q35887367 | Malaria invasion ligand RH5 and its prime candidacy in blood-stage malaria vaccine design |
| Q27230042 | Multiprotein complex between the GPI-anchored CyRPA with PfRH5 and PfRipr is crucial for Plasmodium falciparum erythrocyte invasion |
| Q37582331 | Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria |
| Q92972427 | Neutralising antibodies block the function of Rh5/Ripr/CyRPA complex during invasion of Plasmodium falciparum into human erythrocytes |
| Q37412559 | Neutralization of Plasmodium falciparum merozoites by antibodies against PfRH5. |
| Q35216634 | New antigens for a multicomponent blood-stage malaria vaccine |
| Q37626240 | One-step design of a stable variant of the malaria invasion protein RH5 for use as a vaccine immunogen |
| Q30042821 | P113 is a merozoite surface protein that binds the N terminus of Plasmodium falciparum RH5 |
| Q26853267 | Paths to a malaria vaccine illuminated by parasite genomics |
| Q27230101 | PfRH2b specific monoclonal antibodies inhibit merozoite invasion |
| Q33596068 | PlasmoView: a web-based resource to visualise global Plasmodium falciparum genomic variation |
| Q21131363 | Plasmodium falciparum erythrocyte invasion: combining function with immune evasion |
| Q37247459 | Plasmodium falciparum merozoite surface antigen, PfRH5, elicits detectable levels of invasion-inhibiting antibodies in humans |
| Q28554358 | Plasmodium vivax Reticulocyte Binding Proteins Are Key Targets of Naturally Acquired Immunity in Young Papua New Guinean Children |
| Q26700012 | Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line system |
| Q56342201 | Production, quality control, stability, and potency of cGMP-produced RH5.1 protein vaccine expressed in S2 cells |
| Q37025030 | Progress and prospects for blood-stage malaria vaccines |
| Q35147457 | Quantification of Plasmodium-host protein interactions on intact, unmodified erythrocytes by back-scattering interferometry |
| Q36394182 | Recent advances in recombinant protein-based malaria vaccines |
| Q27321307 | Revealing the sequence and resulting cellular morphology of receptor-ligand interactions during Plasmodium falciparum invasion of erythrocytes |
| Q56342063 | Strain-transcending neutralization of malaria parasite by antibodies against Plasmodium falciparum enolase |
| Q33959038 | Strategies for designing and monitoring malaria vaccines targeting diverse antigens |
| Q36483323 | Structurally conserved erythrocyte-binding domain in Plasmodium provides a versatile scaffold for alternate receptor engagement |
| Q24289322 | Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies |
| Q37699090 | Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody |
| Q46748512 | Synergistic malaria vaccine combinations identified by systematic antigen screening |
| Q26777053 | The Use of Synthetic Carriers in Malaria Vaccine Design |
| Q38196455 | The path of malaria vaccine development: challenges and perspectives |
| Q31153899 | Towards a comprehensive Plasmodium falciparum merozoite cell surface and secreted recombinant protein library |
| Q34988452 | Vaccination with conserved regions of erythrocyte-binding antigens induces neutralizing antibodies against multiple strains of Plasmodium falciparum |
| Q89559300 | Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models |
| Q34785832 | Variant surface antigens of malaria parasites: functional and evolutionary insights from comparative gene family classification and analysis |